// App-Quantinova.ai

9011 : Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.

Researchers

Presenter

  • Justin F. Gainor

Principal Investigators

  • Hira Rizvi

  • Elizabeth Jimenez Aguilar

  • Meghan Mooradian

  • Christine A. Lydon

  • Danyon Anderson

  • Megan Tenet

  • Jennifer L. Sauter

  • Mari Mino-Kenudson

  • Alice Tsang Shaw

  • Mark M. Awad

  • Matthew David Hellmann

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

  • Tumor mutational burden

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved